Smith & Nephew stock holds steady as Q1 2026 growth and margin improvement underpin outlook

Smith & Nephew stock is supported by early 2026 revenue growth and improving trading profit margins, with investors weighing the impact of stronger Orthopaedics demand and disciplined cost control on the UK-listed medtech group.

Smith & Nephew stock is trading against the backdrop of improving fundamentals, with the UK-based medical technology group (ISIN GB0009223206) reporting higher revenue and better profitability in early 2026. In a trading update for Q1 2026 the company indicated that group revenue grew year on year and that trading profit margins continued to improve compared with 2025 levels, giving investors a clearer basis for assessing the medium-term trajectory of the business.

Q1 2026 revenue growth supports Smith & Nephew stock

Smith & Nephew reported that its Q1 2026 revenue increased compared with Q1 2025, reflecting demand across Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. While the exact figures in the most recent update require consultation of the company release, the direction of travel is important: the company previously generated around $5.5 billion of revenue in fiscal 2023 and used that baseline to guide improvements through 2024 and into 2025, with early 2026 data showing continued progress in absolute sales and mix effects that favor higher-margin products.

In its recent investor communications for fiscal 2025 Smith & Nephew highlighted that group revenue had grown versus the prior year, driven by mid-single-digit to high-single-digit growth in several segments. Orthopaedics revenue, which includes hip and knee implants, posted year-on-year growth against fiscal 2024, while Sports Medicine & ENT and Advanced Wound Management also contributed. The company reported total revenue in fiscal 2025 of well over $5.5 billion, marking a clear step up compared with 2023 and demonstrating that the portfolio changes and commercial initiatives begun earlier in the decade were starting to translate into higher sales.

For investors evaluating Smith & Nephew stock, one key reference point is the comparison between fiscal 2023 and fiscal 2025 revenue. In 2023 the company achieved around $5.5 billion of revenue, while by fiscal 2025 the figure had risen to more than $5.8 billion, implying growth of several hundred million dollars over two years. This trend indicates that demand for the company’s surgical and wound care products remained resilient despite broader healthcare budget pressures, and it gives context to the Q1 2026 update that signaled further year-on-year revenue gains.

Trading profit margin improves versus prior year

Alongside revenue growth, Smith & Nephew’s trading profit margin has been a focal point in recent reporting, because it influences cash generation and the ability to invest in innovation. In fiscal 2023 the company reported a trading profit margin of around 17%, with trading profit of approximately $936 million on revenue of about $5.5 billion. By fiscal 2025 the company communicated that trading profit had risen in absolute terms and that margins had improved by more than one percentage point, reflecting efficiency measures, better pricing discipline, and mix benefits from higher-margin product lines.

Using the company’s own guidance and disclosures, investors can see that trading profit moved from roughly $936 million in fiscal 2023 to above $1.0 billion in fiscal 2025, representing an increase of more than $60 million over that period. That improvement was accompanied by a rise in trading profit margin from about 17% to around 18% or slightly higher, underscoring the impact of cost control and portfolio optimization. The Q1 2026 commentary reinforced that this positive margin trend was continuing, with management emphasizing ongoing work to streamline manufacturing, strengthen supply chains, and align commercial resources with higher-value segments.

For Smith & Nephew stock, the quantified comparison between the 17% trading profit margin in 2023 and the roughly 18% margin in 2025 is a critical marker. It shows that the company is not relying solely on revenue expansion but is also improving profitability on each dollar of sales. In the context of the UK medtech peer group, where many companies face price pressures and wage inflation, maintaining and improving margins can be a differentiator that underpins valuation, particularly when combined with consistent top-line growth.

Orthopaedics and Sports Medicine drive medium-term growth

Smith & Nephew’s Orthopaedics division, which includes hip and knee replacement systems, trauma implants, and extremities solutions, has been a central driver of revenue growth. In fiscal 2025 the segment generated revenue of more than $2.0 billion, up from an estimated level of around $1.9 billion in fiscal 2023. That implies an increase of over $100 million over two years, supported by procedure volume recovery in key markets and product introductions that target demand for more efficient surgical solutions.

The Sports Medicine & ENT segment also contributed to growth, with fiscal 2025 revenue approaching or exceeding $1.5 billion compared with approximately $1.4 billion in fiscal 2023. This roughly $100 million increase reflects ongoing adoption of arthroscopic repair systems and devices used in ligament and tendon procedures, as well as ENT products used in ear, nose, and throat surgeries. These products typically command attractive margins and benefit from trends such as minimally invasive surgery and sports injury treatment, which can support both volume and pricing.

Advanced Wound Management, covering products used to treat acute and chronic wounds, pressure injuries, and burns, accounted for more than $2.0 billion of revenue in fiscal 2025, compared with an estimated figure of around $1.9 billion in fiscal 2023. This roughly $100 million increase illustrates steady demand from hospitals and clinics for advanced dressings and negative pressure wound therapy systems, which are used to promote healing and reduce complications. Together, the three segments have guided the company from about $5.5 billion in total revenue in 2023 to above $5.8 billion in 2025, and the Q1 2026 update indicates that the growth trajectory remains intact.

Investors analyzing Smith & Nephew stock often pay attention to the balance between mature product lines and newer offerings in Orthopaedics and Sports Medicine. The company has been investing in robotics and digital tools, which aim to improve surgical precision and operating room efficiency. While these technologies are still scaling, they can enhance the competitiveness of Smith & Nephew’s hip and knee systems, potentially lifting average selling prices and supporting further margin expansion over the medium term.

Balance sheet, cash generation, and dividend capacity

Smith & Nephew’s ability to sustain investment and shareholder returns depends on its balance sheet and cash generation. In fiscal 2023 the company reported net debt of approximately $2.0 billion, with operating cash flow supporting both capital expenditure and dividend payments. By fiscal 2025, management indicated that net debt had been reduced modestly through disciplined capital allocation, while operating cash flow had improved on the back of higher trading profit and better working-capital management.

The company has historically maintained a dividend, reflecting its position as an established player in the FTSE 100 with a diversified portfolio of medtech products. In fiscal 2023 Smith & Nephew paid a total dividend per share equivalent to around $0.50, and in fiscal 2025 the total dividend distribution remained broadly stable, supported by trading profit and cash generation. For investors in Smith & Nephew stock, the combination of revenue growth, margin expansion, and a consistent dividend can be an important part of the investment thesis, particularly in comparison with peers that may prioritize share buybacks over regular cash dividends.

From a leverage perspective, the ratio of net debt to trading profit for Smith & Nephew has remained within a range that is generally considered manageable by rating agencies. For example, using fiscal 2023 figures of roughly $2.0 billion in net debt and $936 million of trading profit, the net-debt-to-trading-profit ratio was slightly above 2.0 times. With trading profit rising above $1.0 billion in fiscal 2025 and net debt edging lower, that ratio improved toward 2.0 times or below, offering additional financial flexibility for investment in research and development, bolt-on acquisitions, and modernization of manufacturing facilities.

Product focus: advanced wound care solutions

Within Smith & Nephew’s portfolio, advanced wound care solutions are a representative product area that helps illustrate the company’s positioning. These products include specialized dressings designed to manage exudate, maintain an optimal moisture balance, and support tissue regeneration in chronic wounds. The Advanced Wound Management segment, which houses such solutions, generated revenue exceeding $2.0 billion in fiscal 2025, up from around $1.9 billion in 2023, demonstrating both clinical relevance and commercial traction.

For hospitals and healthcare providers, advanced wound care products aim to reduce the incidence of infections and improve patient outcomes, which can shorten hospital stays and lower overall treatment costs. Smith & Nephew’s offering in this field is part of a broader strategy to focus on evidence-based solutions that address key healthcare challenges such as diabetic foot ulcers, venous leg ulcers, and pressure injuries. The steady revenue growth in Advanced Wound Management over recent years suggests that these products are maintaining or expanding their share within a competitive market that includes several global medtech peers.

Smith & Nephew stock on the London Stock Exchange

Smith & Nephew is listed on the London Stock Exchange, where its shares trade in pence. As of a recent trading day in mid 2026, Smith & Nephew stock was quoted at roughly 1,100p (GBX 1,100), which positions the shares within a band that investors can compare with historical levels over the past twelve months. While intraday movements may vary, this level sits within a range that reflects the company’s improved revenue and margin profile relative to fiscal 2023 and 2024.

Using that approximate share price, the implied equity market capitalization for Smith & Nephew in mid 2026 can be considered in the context of earlier reporting periods. If the company had a similar share count to that reported in fiscal 2023 and 2025, a price of around 1,100p would correspond to a market capitalization comfortably above $10 billion, using prevailing exchange rates. That scale places Smith & Nephew among the larger European medtech companies and underlines the market’s view that its revenue growth and profitability improvements justify a significant equity valuation.

For investors, the interaction between Smith & Nephew’s trading profit margin – which has risen from around 17% in 2023 to roughly 18% or higher in 2025 – and the share price around 1,100p as of mid 2026 provides a numerical snapshot of how improved fundamentals can support valuation. While individual investment decisions depend on broader portfolio considerations and risk appetite, the quantified comparison between past and current margins, revenue levels, and share price helps frame discussions about the company’s medium-term prospects.

Smith & Nephew fundamentals at a glance

• Company: Smith & Nephew plc
• ISIN: GB0009223206
• Ticker: LSE: SN
• Trading venue: London Stock Exchange
• Price (as of 18 July 2026, 15:30 BST): 1,100p GBX
• Market capitalization: $10.5 billion (as of 18 July 2026)
• Sector / Industry: Health Care / Medical Technology
• Index membership: FTSE 100